Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (201-210 of 471) with videos related to

Pageof 48
Sort By:
European Journal of Heart Failure|May 30, 2002
Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMETPhilip A Poole-Wilson, John G F Cleland, Andrea Di Lenarda, et al.
Journal of Cardiac Failure|May 10, 2005
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)Mihai Gheorghiade, Cesare Orlandi, John C Burnett, et al.
European Journal of Heart Failure|October 31, 2009
Adherence to medication according to sex and age in the CHARM programmeBradi B Granger, Inger Ekman, Christopher B Granger, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 4, 2019
Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rateKen Lee Chin, Timothy Collier, Stuart Pocock, et al.
European Journal of Heart Failure|December 2, 2017
Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failureEmil Wolsk, Brian Claggett, Lars Køber, et al.
European Journal of Heart Failure|July 19, 2016
Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programmeKevin Damman, Scott D Solomon, Marc A Pfeffer, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeMarc A Pfeffer, Karl Swedberg, Christopher B Granger, et al.
European Heart Journal|August 4, 2004
Expert consensus document on beta-adrenergic receptor blockersJosé López-Sendón, Karl Swedberg, John McMurray, et al.
European Heart Journal|November 13, 2008
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failurePutte Abrahamsson, Joanna Dobson, Christopher B Granger, et al.
European Heart Journal|November 7, 2008
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programmeAlain Cohen-Solal, John J V McMurray, Karl Swedberg, et al.
Pageof 48

Showing results (201-210 of 471) with videos related to

Sort By:
Pageof 48
European Journal of Heart Failure|May 30, 2002
Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMETPhilip A Poole-Wilson, John G F Cleland, Andrea Di Lenarda, et al.
Journal of Cardiac Failure|May 10, 2005
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)Mihai Gheorghiade, Cesare Orlandi, John C Burnett, et al.
European Journal of Heart Failure|October 31, 2009
Adherence to medication according to sex and age in the CHARM programmeBradi B Granger, Inger Ekman, Christopher B Granger, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 4, 2019
Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rateKen Lee Chin, Timothy Collier, Stuart Pocock, et al.
European Journal of Heart Failure|December 2, 2017
Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failureEmil Wolsk, Brian Claggett, Lars Køber, et al.
European Journal of Heart Failure|July 19, 2016
Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programmeKevin Damman, Scott D Solomon, Marc A Pfeffer, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeMarc A Pfeffer, Karl Swedberg, Christopher B Granger, et al.
European Heart Journal|August 4, 2004
Expert consensus document on beta-adrenergic receptor blockersJosé López-Sendón, Karl Swedberg, John McMurray, et al.
European Heart Journal|November 13, 2008
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failurePutte Abrahamsson, Joanna Dobson, Christopher B Granger, et al.
European Heart Journal|November 7, 2008
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programmeAlain Cohen-Solal, John J V McMurray, Karl Swedberg, et al.
Pageof 48